未登录 分享 收藏
ELEGANT: Elacestrant vs Standard ET in Women and Men With Node-positive, ER+, HER2-Early Breast Cancer (eBC) With High Risk of Recurrence - A Global, Multicenter, Randomized, Open- label Phase 3 Study ELEGANT研究：Elacestrant与标准ET治疗在淋巴结阳性、ER阳性、HER2阴性早期乳腺癌（eBC）伴高风险复发女性和男性患者中的比较——一项全球、多中心、随机、开放标签III期研究 Bardia, A.; Kaklamani, V.; O'Shaughnessy, J.; Schmid, P.; Beck, J. T.; De Laurentiis, M.; Curigliano, G.; Rugo, H.; Barcenas, C. H.; Gradishar, W. J.; Ignatiadis, M.; Cameron, D. A.; Tonini, G.; Scartoni, S.; Crozier, J.; Nicacio, L. V.; Wasserman, T.; Tolaney, S. M. 分享 收藏
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer 基于Inavolisib的PIK3CA-Mutated晚期乳腺癌治疗 Turner, N. C.; Im, S-A; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Sunpaweravong, P.; Musolino, A.; Li, H.; Zhang, Q.; Nowecki, Z.; Leung, R.; Thanopoulou, E.; Shankar, N.; Lei, G.; Stout, T. J.; Hutchinson, K. E.; Schutzman, J. L.; Song, C.; Jhaveri, K. L. 分享 收藏
Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial Capivasertib (C)联合多西他赛（P）作为转移性三阴性乳腺癌（mTNBC）的一线治疗方案：CAPItello-290 III期试验 Schmid, P.; McArthur, H. L.; Cortes, J.; Xu, B.; Cardoso, F.; Casalnuovo, M. L.; Demirci, U.; Freitas, R., Jr.; Ghosh, J.; Hegg, R.; Iwata, H.; Chuken, Y. A. Lopez; Nechaeva, M.; Robson, M. E.; Villalobos Valencia, R.; Lloyd, A.; D'Cruz, C.; Foxley, A.; Park, Y. H. 分享 收藏
Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+breast cancer in four trials of the West German Study Group Graeser, Monika; Gluz, Oleg; zu Eulenburg, Christine; Kuemmel, Sherko; von Schumann, Raquel; Christgen, Matthias; Wuerstlein, Rachel; Pelz, Enrico; Kreipe, Hans-Heinrich; Schmid, Peter; Thill, Marc; Braun, Michael; Potenberg, Jochem; Schumacher, Claudia; Tio, Joke; Hartkopf, Andreas; Just, Marianne; Schem, Christian; Ludtke-Heckenkamp, Kerstin; Grischke, Eva-Maria; Hilpert, Felix; Kentsch, Angela; Kates, Ronald; Nitz, Ulrike; Harbeck, Nadia 分享 收藏
PARSIFAL-LONG: Extended follow-up of hormone receptor-positive/ HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study Llombart-Cussac, Antonio; Perez-Garcia, Jose Manuel; Bellet-Ezquerra, Meritxell; Dalenc, Florence; Gil-Gil, Miguel; Ruiz-Borrego, Manuel; Gavila, Joaquin; Schmid, Peter; Zamora, Pilar; Wheatley, Duncan; Martinez-de Duenas, Eduardo; Amillano, Kepa; Anton, Antonio; Cottu, Paul; Vinas, Gemma; Petit, Thierry; Tesarova, Petra; Cueva, Juan; Colleoni, Marco; del Prado, Maria Purificacion Martinez; Andres, Raquel; Cabo, Marta Diaz; Victorino, Susana; Sampayo-Cordero, Miguel; Cortes, Javier 分享 收藏
Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction Burrell, Rebecca; Kumar, Sanjeev; McIntosh, Stuart; Pitsinis, Vassilis; King, Polly; Elsberger, Beatrix; Govindarajulu, Sasirekha; Satherley, Lucy; Hadad, Sirwan; Schmid, Peter; Abraham, Jean; Agrawal, Amit; Benson, John; Cheeseman, Danya; Chernukhin, Igor; Forouhi, Parto; Kleidi, Eleftheria; Pike, Cleopatra; Pinilla, Karen; Provenzano, Elena; Qian, Wendi; Carroll, Jason; Baird, Richard 分享 收藏
Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer Rugo, Hope; Schmid, Peter; Nowecki, Zbigniew; Cescon, David; Im, Seock-Ah; Yusof, Mastura; Gallardo, Carlos; Iwata, Hiroji; Barrios, Carlos; Loi, Sherene; Zhou, Xuan; Zhang, Xiaoli; Pan, Wilbur; Karantza, Vassiliki; Cortes, Javier 分享 收藏
INAVO121: Phase III study of inavolisib plus fulvestrant vs alpelisib plus fulvestrant in patients with hormone receptorpositive, HER2-negative, PIK3CAmutated locally advanced or metastatic breast cancer Juric, Dejan; Kalinsky, Kevin; Im, Seock-Ah; Ciruelos, Eva; Bianchini, Giampaolo; Barrios, Carlos; Jacot, William; Schmid, Peter; Loi, Sherene; Rugo, Hope; Craine, Veronica; Hutchinson, Katherine; Flechais, Aulde; Thanopoulou, Eirini; Harbeck, Nadia 分享 收藏
Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756 Cardoso, Fatima; O'Shaughnessy, Joyce; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda; Cescon, David; Fasching, Peter A.; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gabor; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; Andre, Fabrice; Yasojima, Hiroyuki; Liu, Zhenzhen; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya 分享 收藏
ASTEFANIA: a Phase III study of ado- trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy Schmid, Peter; Bachelot, Thomas; Bianchini, Giampaolo; Harbeck, Nadia; Loi, Sherene; Park, Yeon; Prat, Aleix; Gilham, Leslie; Boulet, Thomas; Gochitashvili, Nino; Monturus, Estefania; Lambertini, Chiara; Nyawira, Beatrice; Knott, Adam; Hurvitz, Sara 分享 收藏
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 5 Pusztai, L.; Denkert, C.; O'Shaughnessy, J.; Cortes, J.; Dent, R.; Mcarthur, H.; Kuemmel, S.; Bergh, J.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Zhu, Y.; Pan, W.; Tryfonidis, K.; Schmid, P. 分享 收藏
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom Hanna, Daire; Merrick, Sophie; Ghose, Aruni; Devlin, Michael John; Yang, Dorothy D.; Phillips, Edward; Okines, Alicia; Chopra, Neha; Papadimatraki, Elisavet; Ross, Kirsty; Macpherson, Iain; Boh, Zhuang Y.; Michie, Caroline O.; Swampillai, Angela; Gupta, Sunnia; Robinson, Tim; Germain, Lewis; Twelves, Chris; Atkinson, Charlotte; Konstantis, Apostolos; Riddle, Pippa; Cresti, Nicola; Naik, Jay D.; Borley, Annabel; Guppy, Amy; Schmid, Peter; Phillips, Melissa 分享 收藏
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119 Cortes, Javier; Winer, Eric P.; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Hund, Stephanie; Kulangara, Karina; Karantza, Vassiliki; Mejia, Jaime A.; Ma, Junshui; Jelinic, Petar; Huang, Lingkang; Pruitt, Scott K.; Emancipator, Kenneth 分享 收藏
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial Gebhart, Geraldine; Keyaerts, Marleen; Guiot, Thomas; Flamen, Patrick; Ruiz-Borrego, Manuel; Stradella, Agostina; Bermejo, Begona; Escriva-de-Romani, Santiago; Martinez, Lourdes Calvo; Ribelles, Nuria; Fernandez-Abad, Maria; Albacar, Cinta; Colleoni, Marco; Garrigos, Laia; de Frutos, Manuel Atienza; Dalenc, Florence; Prat, Aleix; Marme, Frederik; Schmid, Peter; Kerrou, Khaldoun; Braga, Sofia; Gener, Petra; Sampayo-Cordero, Miguel; Cortes, Javier; Perez-Garcia, Jose Manuel; Llombart-Cussac, Antonio 分享 收藏
分享 收藏
Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 Cescon, David W.; Schmid, Peter; Rugo, Hope S.; Im, Seock-Ah; Yusof, Mastura Md; Gallardo, Carlos; Lipatov, Oleg; Barrios, Carlos H.; Perez-Garcia, Jose; Iwata, Hiroji; Masuda, Norikazu; Otero, Marco Torregroza; Gokmen, Erhan; Loi, Sherene; Haiderali, Amin; Zhou, Xuan; Guo, Zifang; Nguyen, Allison Martin; Cortes, Javier 分享 收藏
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study pembrolizumab与化疗对转移性三阴性乳腺癌患者健康相关生活质量的影响: 3期随机主题119研究的结果 Schmid, Peter; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Mejia, Jaime A.; Zhou, Xuan; Haiderali, Amin; Nguyen, Allison Martin; Cortes, Javier; Winer, Eric P. 分享 收藏
Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer A Secondary Analysis of a Randomized Clinical Trial Takahashi, Masato; Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; Mcarthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Im, Seock-Ah; Ahn, Jin-Hee; Mukai, Hirofumi; Huang, Chiun-Sheng; Chen, Shin-Cheh; Kim, Min Hwan; Jia, Liyi; Li, Xin Tong; Tryfonidis, Konstantinos; Karantza, Vassiliki; Iwata, Hiroji; Schmid, Peter 分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
BREAST.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏